Skip to main content

Table 2 Adverse events considered related to study medication per dose group

From: Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

Adverse event1 (SOC/PT), n2 (%)

Treatment group

 

256 μg mRNA

640 μg mRNA

1280 μg mRNA

Total N = 44

Total N = 44

N = 3

N = 3

N = 38

Grade 1/2

Grade ≥3

Grade 1/2

Grade ≥3

Grade 1/2

Grade ≥3

Grade 1/2

Grade ≥3

All Grades

Total patients with related AEs

2 (67)

1 (33)

2 (67)

1 (33)

30 (79)

3 (8)

34 (77)

5 (11)

39 (89)

General disorders and administration site reactions

2 (67)

1 (33)

3 (100)

0

32 (84)

0

37 (84)

1 (2)*1

38 (86)

Injection site erythema

2 (67)

0

2 (67)

0

23 (61)

0

27 (61)

0

27 (61)

Injection site reaction

2 (67)

0

1 (33)

0

18 (47)

0

21 (48)

0

21 (48)

Fatigue

2 (67)

0

0

0

6 (16)

0

8 (18)

0

8 (18)

Pyrexia

0

0

1 (33)

0

6 (16)

0

7 (16)

0

7 (16)

Chills

1 (33)

0

0

0

4 (11)

0

5 (11)

0

5 (11)

Influenza-like symptoms

0

0

0

0

5 (13)

0

5 (11)

0

5 (11)

Musculoskeletal and connective tissue disorders3

1 (33)

0

0

0

5 (13)

1 (3)

6 (14)

1 (2) *2

7 (16)

Nervous system disorders4

1 (33)

0

1 (33)

0

4 (11)

0

6 (14)

0

6 (14)

Renal and urinary disorders5

0

0

0

1 (33)

3 (8)

2 (5)

3 (7)

3 (7)*3

6 (14)

Skin and subcutaneous disorders6

0

0

0

0

6 (16)

0

6 (14)

0

6 (14)

Gastrointestinal disorders7

1 (33)

0

0

0

3 (8)

1 (3)

4 (9)

1 (2)*4

5 (11)

  1. 1 Adverse events (AEs) by system organ class (SOC) and/or preferred term (PT) that occurred in at least 10% of patients
  2. 2 Multiple occurrences of the same AE in one patient are counted once
  3. 3 Musculoskeletal and connective tissue disorders includes the following terms: arthralgia, muscle spasms, muscular weakness and pain events
  4. 4 Nervous system disorders includes the following terms: somnolence, tremor, disturbance in attention, dizziness, dysgeusia
  5. 5 Renal and urinary disorders includes the following terms: urinary retention, urinary tract obstruction, dysuria, hydronephrosis, micturition urgency, obstructive uropathy and urinary incontinence
  6. 6 Skin and subcutaneous tissue disorders includes the following terms: erythema, pruritus
  7. 7 Gastrointestinal disorders include the following terms: diarrhea, constipation, abdominal pain, dry mouth, gingival bleeding, vomiting
  8. *1disease progression; *2flank pain; *3urinary retention (n = 2); urinary retention and hydronephrosis (n = 1); *4vomiting